Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder

International Clinical Psychopharmacology

Volumn 18, Issue 1, 2003, Pages 29-33

  Tenney, Nienke H ^a   Denys, Damiaan A J P ^a   Van Megen, Harold J G M ^a   Glas, Gerrit ^b   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Zwolse Poort ^*  (Netherlands)

Author keywords

Obsessive compulsive disorder; Personality; Quality of life; Symptoms; Treatment

Indexed keywords

PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OBSESSIVE COMPULSIVE DISORDER; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOBIOLOGY; QUALITY OF LIFE; RATING SCALE; STATISTICAL ANALYSIS; SYMPTOM;

ADULT; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR;

EID: 0037245216     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200301000-00005     Document Type: Article

References (27)

1. Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC (2000). Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20:645-652.
2. Allgulander C, Cloninger CR, Przybeck TR, Brandt L (1998). Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacol Bull 34:165-166.
3. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Washington DC: American Psychiatric Association Press.
4. Barry MM, Crosby C, Bogg J (1993). Methodological issues in evaluating the quality of life of long-stay patients. J Mental Health 2:43-56.
5. Bebbington PE (1998). Epidemiology of obsessive-compulsive disorder. Br J Psychiatry 35(suppl.):2-6.
6. Bobes J, Gonzalez MP, Bascaran MT, Arango C, Saiz PA, Bousono M (2001). Quality of life and disability in patients with obsessive-compulsive disorder. Eur Psychiatry 16:239-245.
7. Bystritsky A, Saxena S, Maidment K, Vapnik T, Tarlow G, Rosen R (1999). Quality-of-life changes among patients with obsessive-compulsive disorder in a partial hospitalization program. Psychiatr Services 50:412-414.
8. Bystritsky A, Liberman RP, Hwang S, Wallace CJ, Vapnik T, Maindment K, Saxena S (2001). Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders. Depress Anxiety 14:214-218.
9. Cloninger CR, Svrakic DM, Przybeck TR (1993). A psychobiological model of temperament and character. Arch Gen Psychiatry 50:975-990.
10. Denys D, van der Wee N, van Megen HJ, Westenberg HG (2002). Double blind comparison of paroxetine and venlafaxine in obsessive-compulsive disorder. Int J Neuropsychopharmacology 5(suppl.):131-132.
11. Duijsens IJ, Goekoop JG, Spinhoven P, Eurelings-Spinhoven EHM (1997). Instrumenteel onderzoek: de temperament en karakter vragenlijst. Nederlands Tijdschrift voor de Psychologie 52:199-202.
12. Goodman WK, Price LH (1992). Assessment of severity and change in obsessive compulsive disorder. Psychiatr Clin North Am 15:861-869.
13. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmannn RL, Hill CL, et al. (1989). The Yale-Brown Obsessive Compulsive Scale; I. development, use and reliability. Arch Gen Psychiatry 46:1006-1011.
14. Grabe HJ, Meyer C, Hapke U, Rumpf HJ, Freyberger HJ, Dilling H, John U (2000). Prevalence, quality of life and psychosocial function in obsessive-compulsive disorder and subclinical obsessive-compulsive disorder in northern Germany. Eur Arch Psychiatry Clin Neurosci 250:262-268.
15. Hamilton A (1959). Diagnosis and rating of anxiety. Br J Psychiatry 3:67-69.
16. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychology 6:278-296.
17. Hansson L, Eklund M, Bengtsson-Tops A (2001). The relationship of personality dimensions as measured by the temperament and character inventory and quality of life in individuals with schizophrenia or schizoaffective disorder living in the community. Quality Life Res 10:133-139.
18. Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA (1996). Obsessive-compulsive and spectrum disorders: overview and quality of life Issues. J Clin Psychiatry 57:3-6.
19. Kentros MK, Terkelsen K, Hull J, Smith TE, Goodman M (1997). The relationship between personality and quality of life in persons with schizoaffective disorder and schizophrenia. Quality Life Res 6:118-122.
20. Koran LM, Thienemann MI, Davenport R (1996). Quality of life for patients with obsessive-compulsive disoder. Am J Psychiatry 153:783-788.
21. Koran LM, Leventhal JL, Fireman B, Jacobson A (2000). Pharmacotherapy of obsessive-compulsive disorder in a health maintenance organization. Am J Health Syst Pharm 57:1972-1978.
22. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al. (2001). Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286:2947-2955.
23. Oliver J, Huxley PJ, Priebe S, Kaiser W (1997). Measuring the quality of life of severly mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol 32:76-83.
24. Richter J, Eisemann M, Richter G (2000). Temperament and character during the course of unipolar depression among inpatients. Eur Arch Psychiatry Clin Neurosci 250:40-47.
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janaversus J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry 59(suppl.):22-33.
26. Souetre E, Martin P, Lozet H (1996). Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol 11:45-52.
27. van Nieuwenhuizen C, Schene AH, Koeter MW, Huxley PJ (2001). The Lancashire Quality of Life Profile: modification and psychometric evaluation. Soc Psychiatry Psychiatr Epidemiol 36:36-44.